High HSP27 and HSP70 expression levels are independent adverse prognostic factors in primary resected colon cancer.

Bauer, K; Nitsche, U; Slotta-Huspenina, J; Drecoll, E; von Weyhern, CH; Rosenberg, R; Höfler, H; Langer, R

doi:10.1007/s13402-012-0079-3

journal article

Title:: High HSP27 and HSP70 expression levels are independent adverse prognostic factors in primary resected colon cancer.
Document type:: Journal Article; Research Support, Non-U.S. Gov't
Author(s):: Bauer, K; Nitsche, U; Slotta-Huspenina, J; Drecoll, E; von Weyhern, CH; Rosenberg, R; Höfler, H; Langer, R
Abstract:: The expression of Heat Shock Proteins (HSPs) is increased in various cancers and has been shown to correlate with biological tumor behaviour. This study aimed to investigate the impact of HSP70, HSP60 and HSP27 expression in colon cancer.HSP expression was determined by immunohistochemistry on a tissue microarray with 355 primary resected colon carcinomas of all stages. Expression patterns were correlated with pathologic features (UICC pTNM category, tumor grading) and survival.Expression of HSP27, HSP60 and HSP70 ranged from negative to high. There was no correlation between HSP27, HSP60 and HSP70 expression among each other and with UICC pT category, presence of lymph node or distant metastases or tumor grading. High HSP70 expression was associated with worse overall survival (p < 0.001) and was an independent prognostic factor (p = 0.004) in multivariate analysis including the pathological parameters mentioned above. For patients without lymph node or distant metastases (UICC stages I/II) and with complete tumor excision, HSP70 expression was the only independent prognostic factor for survival (p = 0.001) and superior to UICC pT category. In left sided UICC stage I/II carcinomas, high HSP27 expression also had adverse prognostic impact and was an independent prognostic factor (p = 0.016) besides HSP70 (p = 0.002).High HSP70 and HSP27 expression is associated with worse clinical outcome in colon cancer. Determination of tumoral HSP70 and HSP27 may be used as additional biomarker for risk stratification especially for UICC stage I/II patients.
Journal title abbreviation:: Cell Oncol (Dordr)
Year:: 2012
Journal volume:: 35
Journal issue:: 3
Pages contribution:: 197-205
Language:: eng
Fulltext / DOI:: doi:10.1007/s13402-012-0079-3
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/22535481
Print-ISSN:: 2211-3428
TUM Institution:: Chirurgische Klinik und Poliklinik; Institut für Allgemeine Pathologie und Pathologische Anatomie
BibTeX